Young age is associated with ipsilateral breast tumor recurrence after breast conserving surgery and radiation therapy in patients with HER2-positive/ER-negative subtype

Breast Cancer Research and Treatment

Volumn 130, Issue 2, 2011, Pages 499-505

  Kim, Hee Jeong ^a   Han, Wonshik ^b   Yi, On Vox ^a   Shin, Hee Chul ^b   Ahn, Soo Kyung ^b   Koh, Beom Seok ^a   Moon, Hyeong Gon ^b   You, Jong Han ^a   Son, Byung Ho ^a   Ahn, Sei Hyun ^a   Noh, Dong Young ^b  

^a Asan Medical Center   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

Author keywords

Breast conserving surgery; Breast neoplasms; HER2; Recurrence; Subtype; Young age

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; AGE; ARTICLE; BREAST CANCER; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; KOREA; MAJOR CLINICAL STUDY; PARTIAL MASTECTOMY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENCE RISK; RISK FACTOR; TUMOR RECURRENCE;

ADULT; AGE FACTORS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INCIDENCE; KAPLAN-MEIER ESTIMATE; KOREA; MASTECTOMY, SEGMENTAL; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; PROPORTIONAL HAZARDS MODELS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TISSUE ARRAY ANALYSIS;

EID: 82955195768     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-011-1736-3     Document Type: Article

References (40)

1. Colleoni M, Rotmensz N, Peruzzotti G, Maisonneuve P, Orlando L, Ghisini R et al (2006) Role of endocrine responsiveness and adjuvant therapy in very young women (below 35 years) with operable breast cancer and node negative disease. Ann Oncol 17:1497-1503 (Pubitemid 44542034)
2. Han W, Kim SW, Park IA, Kang D, Youn YK, Oh SK et al (2004) Young age: an independent risk factor for disease-free survival in women with operable breast cancer. BMC Cancer 4:82
3. O'Rourke MT, Ellison PT (1993) Age and prognosis in pre-menopausal breast cancer. Lancet 342:60 (Pubitemid 23183948)
4. Han W, Kang SY (2010) Relationship between age at diagnosis and outcome of premenopausal breast cancer: age less than 35 years is a reasonable cut-off for defining young age-onset breast cancer. Breast Cancer Res Treat 119:193-200
5. Ahn SH, Son BH, Kim SW, Kim SI, Jeong J, Ko SS et al (2007) Poor outcome of hormone receptor-positive breast cancer at very young age is due to tamoxifen resistance: nationwide survival data in Korea\-a report from the Korean Breast Cancer Society. J Clin Oncol 25:2360-2368 (Pubitemid 47007614)
6. Bollet MA, Sigal-Zafrani B, Mazeau V, Savignoni A, de la Rochefordiere A, Vincent-Salomon A et al (2007) Age remains the first prognostic factor for loco-regional breast cancer recur-rence in young (<40 years) women treated with breast conserving surgery first, Radiother Oncol, 82, 272-280. (Pubitemid 46350796)
7. Jones HA, Antonini N, Hart AA, Peterse JL, Horiot JC, Collin F et al (2009) Impact of pathological characteristics on local relapse after breast-conserving therapy: a subgroup analysis of the EO-RTC boost versus no boost trial. J Clin Oncol 27:4939-4947
8. Bartelink H, Horiot JC, Poortmans P, Struikmans H, Van den Bogaert W, Barillot I et al (2001) Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation. N Engl J Med 345:1378-1387
9. Botteri E, Bagnardi V, Rotmensz N, Gentilini O, Disalvatore D, Bazolli B et al (2010) Analysis of local and regional recurrences in breast cancer after conservative surgery. Ann Oncol 21: 723-728
10. Zhou P, Gautam S, Recht A (2007) Factors affecting outcome for young women with early stage invasive breast cancer treated with breast-conserving therapy. Breast Cancer Res Treat 101:51-57 (Pubitemid 47555329)
11. Komoike Y, Akiyama F, Iino Y, Ikeda T, Akashi-Tanaka S, Ohsumi S et al (2006) Ipsilateral breast tumor recurrence (IBTR) after breast-conserving treatment for early breast cancer: risk factors and impact on distant metastases. Cancer 106:35-41 (Pubitemid 43032546)
12. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA et al (2000) Molecular portraits of human breast tumours. Nature 406:747-752
13. Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H et al (2001) Gene expression patterns of breast carcinomas dis-tinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98:10869-10874 (Pubitemid 32878711)
14. Albert JM, Gonzalez-Angulo AM, Guray M, Sahin A, Strom EA, Tereffe W et al (2010) Estrogen/progesterone receptor negativity and HER2 positivity predict locoregional recurrence in patients with T1a, b N0 breast cancer. Int J Radiat Oncol Biol Phys 77: 1296-1302
15. Voduc KD, Cheang MCU, Tyldesley S, Gelmon K, Nielsen TO, Kennecke H (2010) Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol 28:1684-1691
16. Nguyen PL, Taghian AG, Katz MS, Niemierko A, Abi Raad RF, Boon WL et al (2008) Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol 26:2373-2378
17. Antonini N, Jones H, Horiot JC, Poortmans P, Struikmans H, Van den Bogaert W et al (2007) Effect of age and radiation dose on local control after breast conserving treatment: EORTC trial 22881-10882. Radiother Oncol 82:265-271 (Pubitemid 46341468)
18. Anders CK, Fan C, Parker JS, Carey LA, Blackwell KL, Klauber-De More N et al (2011) Breast carcinomas arising at a young age: unique biology or a surrogate for aggressive intrinsic subtypes? J Clin Oncol 29:e18-e20
19. Anders CK, Hsu DS, Broadwater G, Acharya CR, Foekens JA, Zhang Y et al (2008) Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. J Clin Oncol 26:3324-3330
20. Cil T, Fishell E, Hanna W, Sun P, Rawlinson E, Narod SA et al (2009) Mammographic density and the risk of breast cancer recurrence afterbreast-conserving surgery. Cancer 115:5780-5787
21. Boyd NF, Rommens JM, Vogt K, Lee V, Hopper JL, Yaffe MJ et al (2005) Mammographic breast density as an intermediate phenotype for breast cancer. Lancet Oncol 6:798-808 (Pubitemid 41430721)
22. Harvey JA (2004) Quantitative assessment of percent breast density: analog versus digital acquisition. Technol Cancer Res Treat 3:611-616 (Pubitemid 40023551)
23. Guo YP, Martin LJ, Hanna W, Banerjee D, Miller N, Fishell E et al (2001) Growth factors and stromal matrix proteins associ-ated with mammographic densities. Cancer Epidemiol Biomark Prev 10:243-248 (Pubitemid 34288536)
24. van Gils CH, Otten JD, Verbeek AL, Hendriks JH (1998) Mammographic breast density and risk of breast cancer: masking bias or causality? Eur J Epidemiol 14:315-320 (Pubitemid 28288451)
25. Haffty BG, Yang Q, Reiss M, Kearney T, Higgins SA, Weidhaas J et al (2006) Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol 24:5652-5657 (Pubitemid 46631305)
26. Millar EKA, Graham PH, O'Toole SA, Mc Neil CM, Browne L, Morey AL et al (2009) Prediction of local recurrence, distant metastases, and death after breast-conserving therapy in early-stage invasive breast cancer using a five-biomarker panel. J Clin Oncol 27:4701-4708
27. Sartor CI (2003) Epidermal growth factor family receptors and inhibitors: radiation response modulators. Semin Radiat Oncol 13:22-30 (Pubitemid 36173257)
28. Pietras RJ, Poen JC, Gallardo D, Wongvipat PN, Lee HJ, Slamon DJ (1999) Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radio-sensitivity of human breast cancer cells overexpressing this oncogene. Cancer Res 59:1347-1355 (Pubitemid 29136268)
29. Rao GS, Murray S, Ethier SP (2000) Radiosensitization of human breast cancer cells by a novel Erb B family receptor tyrosine kinase inhibitor. Int J Radiat Oncol Biol Phys 48:1519-1528
30. No M, Choi EJ, Kim IA (2009) Targeting HER2 signaling pathway for radiosensitization: alternative strategy for therapeutic resistance. Cancer Biol Ther 8:2351-2361
31. Sambade MJ, Camp JT, Kimple RJ, Sartor CI, Shields JM (2009) Mechanism of lapatinib-mediated radiosensitization of breast cancer cells is primarily by inhibition of the Raf>MEK>ERK mitogen-activated protein kinase cascade and radiosensitization of lapatinib-resistant cells restored by direct inhibition of MEK. Radiother Oncol 93:639-644
32. Veronesi U, Cascinelli N, Mariani L, Greco M, Saccozzi R, Luini A et al (2002) Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med 347:1227-1232 (Pubitemid 35176241)
33. Fisher B, Anderson S, Bryant J, Margolese RG, Deutsch M, Fisher ER et al (2002) Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 347:1233-1241 (Pubitemid 35176242)
34. Coulombe G, Tyldesley S, Speers C, Paltiel C, Aquino-Parsons C, Bernstein V et al (2007) Is mastectomy superior to breast-conserving treatment for young women? Int J Radiat Oncol Biol Phys 67:1282-1290 (Pubitemid 46467166)
35. Neuschatz AC, Di Petrillo T, Safaii H, Price LL, Schmidt-Ullrich RK, Wazer DE (2003) Long-term follow-up of a prospective policy of margin-directed radiation dose escalation in breast-conserving therapy. Cancer 97:30-39 (Pubitemid 36033860)
36. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Davidson NE et al (2005) Trastuzumab plus adjuvant chemo-therapy for operable HER2-positive breast cancer. N Engl J Med 353:1673-1684 (Pubitemid 41464706)
37. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I et al (2005) Trastuzumab after adjuvant che-motherapy in HER2-positive breast cancer. N Engl J Med 353:1659-1672 (Pubitemid 41464705)
38. Koukourakis MI, Giatromanolaki A, Galazios G, Sivridis E (2003) Molecular analysis of local relapse in high-risk breast cancer patients: Can radiotherapy fractionation and time factors make a difference? Br J Cancer 88:711-717 (Pubitemid 36411450)
39. Colleoni M, Rotmensz N, Peruzzotti G, Maisonneuve P, Viale G, Renne G et al (2004) Minimal and small size invasive breast cancer with no axillary lymph node involvement: the need for tailored adjuvanttherapies. Ann Oncol 15:1633-1639 (Pubitemid 39562603)
40. Zellars RC, Hilsenbeck SG, Clark GM, Allred DC, Herman TS, Chamness GC et al (2000) Prognostic value of p53 for local failure in mastectomy-treated breast cancer patients. J Clin Oncol 18:1906-1913 (Pubitemid 30261928)